The AstraZeneca (AZN) share price is soaring: here’s what I’d do now

Growing drugs development success has helped lift the AstraZeneca (LON: AZN) share price, but would I buy now? For me, it’s all about valuation.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Back when Pascal Soriot took charge at the then-troubled AstraZeneca (LSE: AZN) in 2012, I didn’t expect a quick fix. No, it was going to take time, money and hard work to get the drugs giant’s development pipeline flowing again. But the market reacted with a rare long-term outlook, and the AstraZeneca share price gradually strengthened.

AstraZeneca shares have almost trebled since Soriot took up the CEO position, while the FTSE 100 has put on just 25%. It helps that AstraZeneca fared relatively well during the pandemic-induced crash. But I can’t help being concerned over one specific question. Has enthusiasm overtaken reality?

I’m talking about valuation here, and how AstraZeneca’s starting to make me suck my teeth and shake my head a bit. The thing is, while the shares have been climbing, earnings haven’t.

Well, EPS did rise in 2020. But there were several years of falling earnings prior to that, with a collapse from more than $4 in 2017, to barely above $1 in 2019. The $2.44 per share recorded in 2020 was a welcome uptick, but it was still way below levels of old.

AstraZeneca share price valuation

Years of weakening earnings, coupled with an accelerating share price, mean only one thing. And that’s a ballooning P/E valuation. On the current AstraZeneca share price, and based on trailing 2020 earnings, we’re looking at a multiple of a shade under 50 now.

Going on forecasts, the forward figure still stands at a little over 40. That’s up in a small-cap growth stock territory, for a FTSE 100 company with a market-cap of more than £133bn.

It doesn’t necessarily mean it’s overvalued. But it does mean AstraZeneca will need to grow its earnings substantially to get that P/E down closer to the Footsie’s average. I’m not suggesting AstraZeneca is an average company that should be on an average valuation. No, better companies can often sustain significantly higher valuations.

But to get the AstraZeneca P/E down only as far as 20, earnings would need to climb to around 430p. That’s close to 2.5 times 2020 earnings.

Long-term potential

Is such earnings growth achievable? I think it is. The real question in my mind is how long will it take? While good news is coming in steadily, investors are usually happy to hold on, and even keep buying.

But all it can take is one set of figures that don’t quite meet the latest elevated expectations, and suddenly we can see a whole host of sellers dumping their shares. Even a quiet spell on the news front can push some away.

And even though Covid-related sales only contribute a tiny portion of the company’s profits, the general pharmaceuticals sector bullishness surely helped lift the AstraZeneca share price. And that effect has to end, eventually.

So what’s the bottom line for me? I think AstraZeneca is an excellent company with the potential to generate profits and dividends for many years to come. And it’s one I’d definitely like to have in my Stocks & Shares ISA.

I just hesitate at the current valuation. I’ll watch, and maybe buy on the dips.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »